Assessment of disease specific immune responses in enteric diseases using dried blood spot (DBS).
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
09
12
2018
accepted:
30
05
2019
entrez:
18
6
2019
pubmed:
18
6
2019
medline:
20
2
2020
Statut:
epublish
Résumé
Blood collection, transportation and storage remain a problem in countries where infrastructure, laboratory facilities and skilled manpower are scarce. This limits evaluation of immune responses in natural infections and vaccination in field studies. We developed methods to measure antigen specific antibody responses using dried blood spot (DBS) in cholera, ETEC and typhoid fever patients as well as recipients of oral cholera vaccine (OCV). We processed heparinized blood for preparing DBS and plasma specimens from patients with, cholera, ETEC and typhoid as well as OCV recipients. We optimized the conventional vibriocidal method to measure vibriocidal antibody response in DBS eluates. We measured responses in DBS samples and plasma (range of titer of 5 to 10240). Vibriocidal titer showed strong agreement between DBS eluates and plasma in cholera patients (ICC = 0.9) and in OCV recipients (ICC = 0.8) using the Bland-Altman analysis and a positive correlation was seen (r = 0.7, p = 0.02 and r = 0.6, p = 0.006, respectively). We observed a strong agreement of lipopolysaccharide (LPS) and cholera toxin B (CTB)-specific antibody responses between DBS eluates and plasma in cholera patients and OCV recipients. We also found agreement of heat labile toxin B (LTB) and membrane protein (MP)-specific antibody responses in DBS eluates and plasma specimen of ETEC and typhoid patients respectively. Our results demonstrate that dried blood specimens can be used as an alternate method for preservation of samples to measure antibody responses in enteric diseases and vaccine trials and can be applied to assessment of responses in humanitarian crisis and other adverse field settings.
Sections du résumé
BACKGROUND
Blood collection, transportation and storage remain a problem in countries where infrastructure, laboratory facilities and skilled manpower are scarce. This limits evaluation of immune responses in natural infections and vaccination in field studies. We developed methods to measure antigen specific antibody responses using dried blood spot (DBS) in cholera, ETEC and typhoid fever patients as well as recipients of oral cholera vaccine (OCV).
METHODOLOGY/PRINCIPLE FINDINGS
We processed heparinized blood for preparing DBS and plasma specimens from patients with, cholera, ETEC and typhoid as well as OCV recipients. We optimized the conventional vibriocidal method to measure vibriocidal antibody response in DBS eluates. We measured responses in DBS samples and plasma (range of titer of 5 to 10240). Vibriocidal titer showed strong agreement between DBS eluates and plasma in cholera patients (ICC = 0.9) and in OCV recipients (ICC = 0.8) using the Bland-Altman analysis and a positive correlation was seen (r = 0.7, p = 0.02 and r = 0.6, p = 0.006, respectively). We observed a strong agreement of lipopolysaccharide (LPS) and cholera toxin B (CTB)-specific antibody responses between DBS eluates and plasma in cholera patients and OCV recipients. We also found agreement of heat labile toxin B (LTB) and membrane protein (MP)-specific antibody responses in DBS eluates and plasma specimen of ETEC and typhoid patients respectively.
CONCLUSION
Our results demonstrate that dried blood specimens can be used as an alternate method for preservation of samples to measure antibody responses in enteric diseases and vaccine trials and can be applied to assessment of responses in humanitarian crisis and other adverse field settings.
Identifiants
pubmed: 31206533
doi: 10.1371/journal.pone.0218353
pii: PONE-D-19-15127
pmc: PMC6578496
doi:
Substances chimiques
Cholera Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0218353Subventions
Organisme : FIC NIH HHS
ID : K43 TW010362
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI130378
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet. 2005 Jul 2-8;366(9479):44-9
pubmed: 15993232
J Gen Microbiol. 1989 Jan;135(1):111-20
pubmed: 2674322
Int J Drug Policy. 2017 Sep;47:77-85
pubmed: 28578863
BMC Infect Dis. 2017 Jan 10;17(1):56
pubmed: 28068914
Bioanalysis. 2012 Jun;4(11):1337-50
pubmed: 22720652
BMC Infect Dis. 2006 Jan 25;6:13
pubmed: 16436203
BMC Cancer. 2015 Apr 11;15:265
pubmed: 25886002
Epidemiol Infect. 2002 Aug;129(1):139-45
pubmed: 12211581
Clin Diagn Lab Immunol. 1994 Jan;1(1):51-4
pubmed: 7496922
Infect Immun. 2010 May;78(5):2117-24
pubmed: 20176796
J Virol Methods. 2013 Nov;193(2):503-7
pubmed: 23891874
J Clin Immunol. 2015 Aug;35(6):573-82
pubmed: 26275445
Mol Cell Proteomics. 2013 Mar;12(3):781-91
pubmed: 23221968
Infect Immun. 1992 Nov;60(11):4961-4
pubmed: 1356934
Clin Diagn Lab Immunol. 1995 Nov;2(6):685-8
pubmed: 8574829
Int Arch Allergy Appl Immunol. 1984;75(1):38-43
pubmed: 6746103
AIDS Rev. 2010 Oct-Dec;12(4):195-208
pubmed: 21179184
J Clin Microbiol. 2009 Apr;47(4):1107-18
pubmed: 19193835
J Med Virol. 2011 Feb;83(2):208-17
pubmed: 21181914
Acta Trop. 2002 Feb;81(2):159-65
pubmed: 11801223
J Vis Exp. 2014 Jan 28;(83):e50973
pubmed: 24513728
Am J Trop Med Hyg. 2016 Feb;94(2):322-326
pubmed: 26711525
Clin Chem Lab Med. 2009;47(10):1259-64
pubmed: 19751141
Pediatr Infect Dis J. 2009 Feb;28(2):79-85
pubmed: 19116602
N Engl J Med. 2014 May 29;370(22):2111-20
pubmed: 24869721
J Infect Dis. 1984 Jun;149(6):884-93
pubmed: 6736680
PLoS Negl Trop Dis. 2015 Apr 07;9(4):e0003619
pubmed: 25849611
Clin Infect Dis. 2013 Apr;56(8):1123-31
pubmed: 23362293
PLoS Negl Trop Dis. 2018 Jan 29;12(1):e0006196
pubmed: 29377882
Infect Immun. 1996 Jan;64(1):10-5
pubmed: 8557325
J Med Virol. 2015 Sep;87(9):1491-9
pubmed: 25988945
Clin Vaccine Immunol. 2009 Nov;16(11):1587-94
pubmed: 19741090
Lancet Infect Dis. 2013 Dec;13(12):1050-6
pubmed: 24140390
Microb Pathog. 1988 Sep;5(3):169-75
pubmed: 3216777
J Clin Microbiol. 2014 Feb;52(2):578-86
pubmed: 24478491
N Engl J Med. 2016 May 5;374(18):1723-32
pubmed: 27144848
PLoS Negl Trop Dis. 2014 Jul 17;8(7):e3031
pubmed: 25032802
Rev Inst Med Trop Sao Paulo. 1994 Mar-Apr;36(2):131-8
pubmed: 7997788
Lancet Infect Dis. 2012 Nov;12(11):837-44
pubmed: 22954655
J Infect Dis. 2011 Jul;204 Suppl 1:S564-9
pubmed: 21666214
Antimicrob Agents Chemother. 2013 Oct;57(10):4999-5004
pubmed: 23896473
Int J Tuberc Lung Dis. 1997 Dec;1(6):493-7
pubmed: 9487445